Marginal Zone Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) acalabrutinib Sensitive : A2 NCCN - 1wk	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week acalabrutinib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	axicabtagene ciloleucel Sensitive: A2 - Guideline axicabtagene ciloleucel Sensitive : A2	axicabtagene ciloleucel Sensitive: A2 - Guideline axicabtagene ciloleucel Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	obinutuzumab Sensitive: A2 - Guideline obinutuzumab Sensitive : A2	obinutuzumab Sensitive: A2 - Guideline obinutuzumab Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	G-CHOP Sensitive: A2 - Guideline G-CHOP Sensitive : A2	G-CHOP Sensitive: A2 - Guideline G-CHOP Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	tisagenlecleucel-T Sensitive: A2 - Guideline tisagenlecleucel-T Sensitive : A2	tisagenlecleucel-T Sensitive: A2 - Guideline tisagenlecleucel-T Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	O-CVP Sensitive: A2 - Guideline O-CVP Sensitive : A2	O-CVP Sensitive: A2 - Guideline O-CVP Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B
MYD88 mutation	Marginal Zone Lymphoma	MYD88 mutation	Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CARD11 mutation	Marginal Zone Lymphoma	CARD11 mutation	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
KMT2D mutation	Marginal Zone Lymphoma	KMT2D mutation	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
MYD88 L265P	Marginal Zone Lymphoma	MYD88 L265P	Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
TNFAIP3 mutation	Marginal Zone Lymphoma	TNFAIP3 mutation	Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CD5 positive	Marginal Zone Lymphoma	CD5 positive	Marginal Zone Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
LDH elevation	Marginal Zone Lymphoma	LDH elevation	Marginal Zone Lymphoma	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3
TNFAIP3 mutation	Marginal Zone Lymphoma	TNFAIP3 mutation	Marginal Zone Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
MYD88 mutation	Marginal Zone Lymphoma	MYD88 mutation	Marginal Zone Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
TP53 mutation + MET amplification + PD-L1 overexpression	Marginal Zone Lymphoma	TP53 mutation + MET amplification + PD-L1 overexpression	Marginal Zone Lymphoma	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation	Marginal Zone Lymphoma	NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation	Marginal Zone Lymphoma	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
BIRC3-MALT1 fusion	Marginal Zone Lymphoma	BIRC3-MALT1 fusion	Marginal Zone Lymphoma	R-CHOP Sensitive: C4 – Case Studies R-CHOP Sensitive : C4	R-CHOP Sensitive: C4 – Case Studies R-CHOP Sensitive : C4

Marginal Zone Lymphoma

Associations(34)

Associations
(34)